Dendreon Announces Presentation Of PROVENGE® (sipuleucel-T) Data At The 2014 Genitourinary Cancer Symposium (ASCO GU)

January 30, 2014 – Dendreon Corporation (NASDAQ: DNDN) today announced the presentation of four PROVENGE ® (sipuleucel-T) abstracts and one abstract for DN24-02, an investigational active cellular immunotherapy, from ongoing clinical trials at the 2014 Genitourinary Cancers Symposium (ASCO GU) from January 30-February 1, 2014 in San Francisco, California.

“The PROVENGE and DN24-02 research presented at this year's ASCO GU Symposium demonstrate Dendreon's ongoing commitment to our immuno-oncology franchise and patients in need of new and innovative treatment options for cancer,” said Andrew S. Sandler, M.D., executive vice president and chief medical officer at Dendreon. “These data further elucidate the mechanism underlying the PROVENGE treatment effect and further our understanding of the role of immunotherapy in cancer treatment.”

The data featuring PROVENGE and DN24-02 studies include:
  • Antigen Spread and Survival with Sipuleucel-T in Patients with Advanced Prostate Cancer (Abstract #88). In the pivotal Phase III IMPACT study, post-hoc subset data demonstrate PROVENGE treatment may result in humoral antigen spread, a process by which the immune response broadens over time to target multiple cancer-related antigens. Additionally, this effect was found to be associated with improved overall survival. These results contribute to an understanding of the mechanism of action for PROVENGE and may enable identification of post-treatment biomarkers of clinical outcome. Poster Session A: Prostate Cancer, Thursday, January 30, 11:30 AM – 1:00 PM PST, Golden Gate Hall Lead Author: Charles G. Drake, M.D., Ph.D., Johns Hopkins University School of Medicine, Baltimore, MD
  • Effect of Prior Abiraterone (ABI) or Enzalutamide (ENZ) on Sipuleucel-T (sip-T) Manufacture in PROCEED Patients (pts) (Abstract #185). A subgroup analysis from the Phase IV PROCEED registry suggests that prior treatment with abiraterone acetate or enzalutamide does not negatively impact PROVENGE manufacturing or product parameters. These results are consistent with prior analyses demonstrating a positive PROVENGE treatment immune effect in patients who have received prior therapies. Poster Session A: Prostate Cancer, Thursday, January 30, 11:30 AM – 1:00 PM PST, Golden Gate Hall Lead Author: Nicholas J. Vogelzang, M.D., Comprehensive Cancer Centers of Nevada, Las Vegas, NV

“Data from the Phase III IMPACT study demonstrate that treatment with sipuleucel-T may result in humoral antigen spread, which was found to be associated with improved overall survival,” said Daniel Petrylak, M.D., professor of medicine, director of Genitourinary Oncology, co-director of Signal Transduction Research Program, Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven. “These results are particularly exciting because they further our understanding of the sipuleucel-T mechanism of action and may enable identification of post-treatment biomarkers of clinical outcome.”

If you liked this article you might like

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions

Stock Market Today: S&P 500 Eyes Strong Finish for 2014; Alibaba Spikes